3 Factors Contribute to Taiwan’s Success Against COVID-19: Former VP
Ever wondered how Taiwan, despite its geographical proximity to China, managed to keep the COVID-19 at bay? Well, Taiwan’s former vice president, Chen Chien-jen, has some answers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005239/en/
Then Vice President Chen Chien-jen speaks to the media at the Presidential Office Building on May 14, thanking the Taiwanese people for contributing to the success in the battle against the COVID-19, a few days before he left office. CNA photo May 14, 2020
“I think there were three important factors that contributed to this: a prudent attitude in dealing with COVID-19, prompt actions in responding to different situations, and forward planning before a crisis,” Chen said in a webcast program produced by the Talent Circulation Alliance and the American Institute in Taiwan June 24.
One example of these was Taiwan’s learning of the situation in Wuhan, where the coronavirus was first detected in late 2019, from a bulletin board system in Taiwan and immediately screening passengers arriving from that city, Chen said.
Chen, an epidemiologist, said Taiwan also began taking measures to prevent hospital infections, enhanced contact tracing, and quarantined people who had close contact with confirmed cases.
In addition, the activation of the Central Epidemic Command Center to coordinate government response, the requisition of face masks, and the pre-positioning of medical supplies all contributed to Taiwan’s success against COVID-19, Chen said.
Taiwan was able to increase its daily production capacity of surgical masks from 1.88 million to 20 million in just over a month.
The government’s detailed explanation of its coronavirus prevention measures gave the public confidence in its ability to handle the situation, resulting in people abiding by government instructions, including washing hands frequently, wearing face masks, and following home quarantine rules, he said.
Chen, who served as Taiwan's health minister during the Severe Acute Respiratory Syndrome (SARS) outbreak in 2003, also stressed the importance of talent circulation in epidemic prevention cooperation.
“No country can combat any emerging communicable disease alone,” Chen said.
During SARS, for example, Chen said Taiwan did not receive help from the WHO because of its ongoing exclusion from the U.N. special agency. Fortunately, with the assistance of 20 specialists sent by the U.S. Centers for Disease Control and Prevention, Taiwan was able to weather the health crisis, he said.
Meanwhile, the U.S. specialists brought back what they had learned from Taiwan and contributed to the setting of standard procedures in America in dealing with SARS, Chen said, “The world can be a better place if people cooperate with each other, circulate talent, and share technologies.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200713005239/en/
Contact information
Central News Agency
Name: Jay Chen
Email: jenjey.chen@cna.com.tw
Phone: +886-2-25051180 ext. 100
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release
Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
